Figure 2.

Siglec-7/9, cross-talking with sialic acids (Sia) on the surface of target cells, can inhibit the cytotoxicity of NK cells. The interaction between siglec7/9 and Sia can lead to the phosphorylation of ITIM and recruit SHP-1 and SHP-2, which will suppress the NK cell activation, and resulting in disease progression.